8-K: IN8bio Announces Promising Phase 1 Trial Results for INB-200 Glioblastoma Therapy

IN8bio reports encouraging clinical data from its Phase 1 trial of INB-200, showing durable remissions and immune cell infiltration in glioblastoma patients.

Summary

• IN8bio presented positive results from its Phase 1 trial of INB-200 for glioblastoma at the Society for Neuro-Oncology Annual Meeting.
• The trial showed that 50% of patients receiving repeated doses of INB-200 remained alive and in remission beyond the expected median overall survival from standard treatment.
• Biopsies confirmed the presence of gamma-delta T cells and other immune cells within the brain tumor microenvironment after treatment.
• Patients in the multi-dose cohorts showed a trend towards improved peripheral T cell recovery, suggesting potential immune system benefits.
• The majority of patients exceeded their expected progression-free survival, with one patient remaining progression-free at 40.5 months post-treatment.
• The trial assessed three dosing regimens, with 13 patients enrolled and treated.
• 92% of evaluable patients surpassed the median standard-of-care progression-free survival of 6.9 months.
• No treatment-related serious adverse events were reported, with only mild toxicities related to standard chemotherapy observed.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with significant improvements in patient outcomes and a good safety profile. The language is optimistic and the results are promising for the future of the therapy.

Positives

• The study showed a significant increase in median progression-free survival compared to standard treatment.
• The presence of gamma-delta T cells in tumor biopsies confirms the therapy's mechanism of action.
• The treatment was well-tolerated with no serious adverse events.
• Some patients have returned to their occupations, indicating an improvement in their quality of life.
• The data suggests that repeat dosing of gamma-delta T cells may benefit the peripheral immune environment.

Negatives

• Three patients who received a single dose did not achieve the same positive outcomes as those who received multiple doses.
• The most common adverse events were Grade 1-2 toxicities consisting of white blood cell and platelet count decreases related to standard-of-care TMZ.

Risks

• The company may not achieve anticipated milestones, including the advancement of clinical development plans.
• There are uncertainties inherent in the initiation and completion of preclinical studies and clinical trials.
• The company may be unable to raise additional capital, which could impact development programs.
• The company relies on third parties, including licensors and clinical research organizations.
• There is a risk that trials and studies may be delayed and may not have satisfactory outcomes.

Future Outlook

The company is focused on advancing its clinical development plans and exploring the potential of its gamma-delta T cell therapies for solid tumor cancers. They are also working to achieve anticipated milestones.

Management Comments

• Burt Nabors, M.D., stated that the data is indicative of positive treatment effects and highlights the potential of IN8bio's genetically modified gamma-delta T cells.
• William Ho, co-founder and CEO of IN8bio, believes the treatment represents a significant advancement in the treatment of solid tumor cancers such as GBM.

Industry Context

This announcement is significant in the context of the broader immuno-oncology field, where novel cell therapies are being developed to target difficult-to-treat cancers like glioblastoma. The use of gamma-delta T cells is a unique approach that could offer advantages over traditional T cell therapies.

Comparison to Industry Standards

• The median PFS of 6.9 months for the standard-of-care Stupp regimen is a benchmark for glioblastoma treatment.
• The trial results showed a 79% increase in median PFS compared to the Stupp regimen, indicating a significant improvement.
• The median PFS of 11.1 months in the control arm and 27.7 months in the experimental arm for IDH-mutant patients in a recently published clinical trial provides a comparison for the IN8bio results.
• The fact that one patient remains progression free at 40.5 months is a very positive result compared to the industry standard.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably.
• Patients with glioblastoma may have a new treatment option with the potential for improved outcomes.
• Employees of IN8bio may be encouraged by the progress of the company's research and development efforts.

Next Steps

• The company will continue to monitor the patients in the Phase 1 trial.
• IN8bio will continue to advance its clinical development plans for INB-200 and other gamma-delta T cell therapies.

Key Dates

Keywords

INB-200, Glioblastoma, Gamma-delta T cells, Immunotherapy, Clinical Trial, Cancer, DeltEx, Progression-Free Survival, Remission, Neuro-Oncology